(Q39385998)

11 September 2017

TSA-induced JMJD2B downregulation is associated with cyclin B1-dependent survivin degradation and apoptosis in LNCap cells (English)

1 reference

11 September 2017

Shan Zhu

1

1 reference

11 September 2017

Yueyang Li

2

1 reference

11 September 2017

Li Zhao

3

1 reference

11 September 2017

Pingfu Hou

4

1 reference

11 September 2017

Chenyan Shangguan

5

1 reference

11 September 2017

Ruosi Yao

6

1 reference

11 September 2017

Weina Zhang

7

1 reference

11 September 2017

Yu Zhang

8

1 reference

11 September 2017

Jiang Tan

9

1 reference

11 September 2017

Baiqu Huang

10

1 reference

11 September 2017

Jun Lu

11

1 reference

11 September 2017

1 July 2012

1 reference

Journal of Cellular Biochemistry

11 September 2017

1 reference

11 September 2017

113

1 reference

11 September 2017

7

1 reference

11 September 2017

2375-2382

1 reference

Cdh1-APC/C, cyclin B-Cdc2, and Alzheimer's disease pathology

11 September 2017

1 reference

The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.

21 January 2018

1 reference

How APC/C orders destruction

21 January 2018

1 reference

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death

21 January 2018

1 reference

Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells

21 January 2018

1 reference

Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells

21 January 2018

1 reference

Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin

21 January 2018

1 reference

p53 in trichostatin A induced C6 glioma cell death

21 January 2018

1 reference

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development

21 January 2018

1 reference

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

Histone deacetylase as a therapeutic target

21 January 2018

1 reference

Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin

21 January 2018

1 reference

A p34(cdc2) survival checkpoint in cancer

21 January 2018

1 reference

Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells

21 January 2018

1 reference

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad.

21 January 2018

1 reference

Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis

21 January 2018

1 reference

Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases

21 January 2018

1 reference

The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth

21 January 2018

1 reference

Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCB.24109

1 reference

11 September 2017

1 reference